Cell line · CVCL_0079
697
Cancer cell line, Homo sapiens. Childhood B acute lymphoblastic leukemia. 42 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. 697. Cell lines, record CVCL_0079. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0079
On this page
Cell line
As Cellosaurus gives it.
- Name
- 697
- Accession
- CVCL_0079
- RRID
- RRID:CVCL_0079
- Synonyms
- Line 697, EU-3, Emory University-3
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 12Y
- Category
- Cancer cell line
- Diseases
Childhood B acute lymphoblastic leukemia (NCIt C9140); B acute lymphoblastic leukemia with t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1) (NCIt C80347); B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3) (ORDO Orphanet_585956)
- Derived from
- Bone marrow (in situ)
- Secondary accessions
- CVCL_8861
- Entry created
- 2012-04-04
- Entry updated
- 2025-08-14
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers42
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| ETV6 Rearrangement Suppresses CDKN1B Transcription by Disrupting an Intragenic Super-enhancer in Acute Lymphoblastic Leukemia. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. | Leukemia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Novel immunotherapeutics against LGR5 to target multiple cancer types. | EMBO Mol Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| SJPedPanel: A Pan-Cancer Gene Panel for Childhood Malignancies to Enhance Cancer Monitoring and Early Detection. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1. | J Immunother Cancer | 2024 | Its Methods give the RRID and name the line | PubMed | |
| 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. | Cell Genom | 2023 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 42
See all 42 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Derived from it | 697-R | CVCL_D3Z6 |
Source Cell lines
Cell banks2
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| DSMZ | ACC-42 | DSMZ | |
| IZSLER | BS TCL 241 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0079
GET https://conductscience.org/api/cell-lines/v1/CVCL_0079/papers?page=2